Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$72.47
$67.07
$54.11
$89.98
$27.96B1.455.10 million shs8.57 million shs
Humana Inc. stock logo
HUM
Humana
$360.84
+0.1%
$285.88
$163.11
$380.86
$43.30B0.761.26 million shs3.57 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$228.37
0.0%
$230.61
$149.04
$251.71
$549.78B0.267.51 million shs18.99 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,098.78
+0.0%
$1,016.10
$623.78
$1,182.73
$1.03T0.532.96 million shs4.45 million shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
0.00%-3.85%+0.79%+8.24%-10.54%
Humana Inc. stock logo
HUM
Humana
0.00%-4.90%+19.04%+112.33%+48.13%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.00%-5.07%-1.43%-3.09%+51.47%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%-3.36%+5.46%+21.37%+40.10%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$72.47
$67.07
$54.11
$89.98
$27.96B1.455.10 million shs8.57 million shs
Humana Inc. stock logo
HUM
Humana
$360.84
+0.1%
$285.88
$163.11
$380.86
$43.30B0.761.26 million shs3.57 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$228.37
0.0%
$230.61
$149.04
$251.71
$549.78B0.267.51 million shs18.99 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,098.78
+0.0%
$1,016.10
$623.78
$1,182.73
$1.03T0.532.96 million shs4.45 million shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
0.00%-3.85%+0.79%+8.24%-10.54%
Humana Inc. stock logo
HUM
Humana
0.00%-4.90%+19.04%+112.33%+48.13%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.00%-5.07%-1.43%-3.09%+51.47%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%-3.36%+5.46%+21.37%+40.10%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DexCom, Inc. stock logo
DXCM
DexCom
2.92
Moderate Buy$84.8317.06% Upside
Humana Inc. stock logo
HUM
Humana
2.25
Hold$291.35-19.26% Downside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.74
Moderate Buy$253.0410.81% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,227.7411.74% Upside

Current Analyst Ratings Breakdown

Latest HUM, LLY, DXCM, and JNJ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/15/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
DowngradeBuy (B)Buy (B-)
6/15/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform
6/15/2026
Humana Inc. stock logo
HUM
Humana
Reiterated RatingNeutral
6/15/2026
DexCom, Inc. stock logo
DXCM
DexCom
Reiterated RatingOverweight$75.00 ➝ $88.00
6/12/2026
Humana Inc. stock logo
HUM
Humana
UpgradeSell (D+)Hold (C-)
6/11/2026
Humana Inc. stock logo
HUM
Humana
Reiterated RatingNeutral
6/11/2026
Humana Inc. stock logo
HUM
Humana
Boost Price Target$250.00 ➝ $370.00
6/10/2026
DexCom, Inc. stock logo
DXCM
DexCom
Set Price Target$95.00
6/10/2026
DexCom, Inc. stock logo
DXCM
DexCom
Reiterated RatingBuy$75.00 ➝ $95.00
6/9/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,330.00 ➝ $1,350.00
6/9/2026
DexCom, Inc. stock logo
DXCM
DexCom
Set Price TargetOutperform$75.00 ➝ $85.00
(Data available from 6/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DexCom, Inc. stock logo
DXCM
DexCom
$4.82B5.80$2.77 per share26.17$7.04 per share10.29
Humana Inc. stock logo
HUM
Humana
$129.66B0.33$24.07 per share14.99$147.47 per share2.45
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$96.36B5.70$14.11 per share16.18$33.85 per share6.75
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$72.25B14.32$25.14 per share43.70$28.07 per share39.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DexCom, Inc. stock logo
DXCM
DexCom
$836.30M$2.3430.9723.841.1319.31%33.33%13.19%7/29/2026 (Estimated)
Humana Inc. stock logo
HUM
Humana
$1.19B$9.3538.5924.102.050.82%10.45%3.75%7/29/2026 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$26.80B$8.6526.4018.122.2421.83%32.60%13.29%7/15/2026 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1539.0324.641.2034.98%105.77%23.76%8/5/2026 (Estimated)

Latest HUM, LLY, DXCM, and JNJ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/15/2026Q2 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.83N/AN/AN/A$24.96 billionN/A
4/30/2026Q1 2026
DexCom, Inc. stock logo
DXCM
DexCom
$0.47$0.56+$0.09$0.51$1.17 billion$1.19 billion
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
4/29/2026Q1 2026
Humana Inc. stock logo
HUM
Humana
$9.97$10.31+$0.34$9.83$39.37 billion$39.65 billion
4/14/2026Q1 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.68$2.70+$0.02$2.14$23.60 billion$24.06 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Humana Inc. stock logo
HUM
Humana
$3.540.98%+7.20%37.86%N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.362.35%+5.25%61.97%64 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.63%+15.18%24.58%11 Years

Latest HUM, LLY, DXCM, and JNJ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/15/2026
Humana Inc. stock logo
HUM
Humana
quarterly$0.88501.79%6/26/20266/26/20267/31/2026
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.69%5/15/20265/15/20266/10/2026
4/14/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.342.33%5/26/20265/26/20266/9/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DexCom, Inc. stock logo
DXCM
DexCom
0.42
1.95
1.64
Humana Inc. stock logo
HUM
Humana
0.66
1.77
1.77
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.46
1.03
0.77
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10

Institutional Ownership

CompanyInstitutional Ownership
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Humana Inc. stock logo
HUM
Humana
92.38%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
DexCom, Inc. stock logo
DXCM
DexCom
0.28%
Humana Inc. stock logo
HUM
Humana
0.20%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
CompanyEmployeesShares OutstandingFree FloatOptionable
DexCom, Inc. stock logo
DXCM
DexCom
11,000385.87 million384.79 millionOptionable
Humana Inc. stock logo
HUM
Humana
67,060120.06 million119.82 millionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,2002.41 billion2.40 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable

Recent News About These Companies

A person wearing a gray shirt displays a continuous glucose monitor sensor on their upper arm.
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend (LLY)
...
Tobam Boosts Stake in Eli Lilly and Company $LLY

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
DexCom stock logo

DexCom NASDAQ:DXCM

$72.47 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$73.40 +0.93 (+1.29%)
As of 06/18/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Humana stock logo

Humana NYSE:HUM

$360.84 +0.19 (+0.05%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$360.00 -0.84 (-0.23%)
As of 06/18/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of pharmacy benefit manager business. Further, it operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. The company sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$228.37 -0.02 (-0.01%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$228.54 +0.17 (+0.08%)
As of 06/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,098.78 +0.21 (+0.02%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$1,101.49 +2.71 (+0.25%)
As of 06/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.